Astex Pharmaceuticals, Inc. (NASDAQ:ASTX)

CAPS Rating: 3 out of 5

A pharmaceutical company dedicated to the discovery, development and commercialization of therapies to treat patients with cancer.

Results 1 - 20 of 36 : 1 2 Next »

Recs

0
Member Avatar 2win (< 20) Submitted: 5/13/2013 7:53:03 AM : Outperform Start Price: $5.51 ASTX Score: -4.01

AB bullish engulfing

Recs

0
Member Avatar NoblyNaive (84.82) Submitted: 4/26/2013 1:07:44 PM : Outperform Start Price: $6.55 ASTX Score: -22.72

Despicable P/E ratio, but pitches by Cramer on other biotechnology firms has led me to discount this a bit. EPS and revenue growths are impressive. So is the stock price action.

April 26: As of about April 15, 2013, I became long ASTX (with real mony, no less), and still am long.

Recs

0
Member Avatar awallejr (80.10) Submitted: 10/23/2012 6:51:40 PM : Outperform Start Price: $2.60 ASTX Score: +89.68

ZZ.

Recs

0
Member Avatar reachmygoals1 (< 20) Submitted: 9/14/2012 9:58:09 AM : Outperform Start Price: $4.07 ASTX Score: +25.74

going up immediately, will surge when expected eu approval for AML on Dacogen by end of September. stay tuned

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 4/7/2012 3:43:23 PM : Outperform Start Price: $1.80 ASTX Score: +177.95

A wonder in their industry. A biotech with actual revenues and a deep pipeline.

Recs

0
Member Avatar Imhilion (68.87) Submitted: 2/12/2012 8:42:23 PM : Outperform Start Price: $2.06 ASTX Score: +138.03

Technical Indicators!

Recs

0
Member Avatar BuffettJunior1 (98.12) Submitted: 2/7/2012 7:19:53 PM : Outperform Start Price: $2.27 ASTX Score: +113.55

Cheap biotech with huge potential.

Recs

0
Member Avatar Teknowizz (97.65) Submitted: 2/3/2012 2:29:45 PM : Outperform Start Price: $2.88 ASTX Score: +63.15

FDA Advisory Committee on Feb 9th; if positive approval in March is likely. Has already risen a lot, but still....

Recs

0
Member Avatar seattle1218 (< 20) Submitted: 1/27/2012 6:05:11 PM : Outperform Start Price: $2.66 ASTX Score: +74.84

Several drugs in the pipeline, will rise in value at least until it reaches the point of fda approval which is March 9, 1012. I may sell before that day.

Recs

0
Member Avatar portefeuille (99.75) Submitted: 12/15/2011 9:34:31 PM : Outperform Start Price: $1.87 ASTX Score: +148.26

There are currently 2500 ASTX shares in my "fund" with break-even of around 0.53 USD.
http://caps.fool.com/Blogs/fund-trades/678775.

Recs

0
Member Avatar niggyt (36.50) Submitted: 4/20/2011 3:48:59 PM : Outperform Start Price: $2.64 ASTX Score: +78.84

They have cash.

Recs

0
Member Avatar rocknpopstocks (< 20) Submitted: 1/21/2011 2:56:52 PM : Outperform Start Price: $2.93 ASTX Score: +54.40

SuperGen is due.

Recs

0
Member Avatar 21popsontop (< 20) Submitted: 11/12/2010 12:00:53 PM : Outperform Start Price: $2.69 ASTX Score: +61.89

Drugs and longshots that could get super real.

Recs

0
Member Avatar RickyMojo (< 20) Submitted: 4/8/2010 11:40:36 PM : Outperform Start Price: $3.20 ASTX Score: +28.61

Cure for cancer?

Recs

0
Member Avatar zackmax (35.72) Submitted: 3/11/2010 3:41:14 PM : Outperform Start Price: $3.25 ASTX Score: +21.57

ccest compte

Recs

0
Member Avatar craigt101 (84.72) Submitted: 11/25/2009 5:40:11 PM : Outperform Start Price: $2.74 ASTX Score: +46.80

Well heeled, financially...a comfortable moat...provides lots of room for R&D without feeling the pinch. Management appears to have built and strong model for developing cancer and related therapies that cover a broad spectrum of life-threatening diseases. I originally bought in at $2.22 and will give it several years. Who knows...maybe a buyout is down the line, as well.

Recs

0
Member Avatar libertybrewcity (< 20) Submitted: 11/2/2009 5:13:10 PM : Outperform Start Price: $2.37 ASTX Score: +66.81

lots of cash, pipeline with good potential

Recs

0
Member Avatar topsecret10 (< 20) Submitted: 10/13/2009 6:32:30 PM : Outperform Start Price: $2.56 ASTX Score: +57.33

Lots of Insider buying here..... SuperGen is a pharmaceutical company whose mission is to prolong, improve the quality of and ultimately, save the lives of those people afflicted with life-threatening diseases, especially cancer.
The company possesses a broad portfolio of proprietary cancer therapies that target a variety of solid tumors, hematological malignancies and blood disorders, offering renewed hope to patients who suffer from these illnesses.
The company is led by a seasoned management team with extensive experience in all aspects of the oncology pharmaceutical industry. TS

Recs

0
Member Avatar ramgee1 (< 20) Submitted: 7/29/2009 5:01:50 AM : Outperform Start Price: $2.75 ASTX Score: +24.44

They have significant cash and cash flow to enable the development of their pipeline of drug candidates. They are a significant buyout possibility.

Recs

0
Member Avatar realworld2 (< 20) Submitted: 7/24/2009 11:56:52 PM : Outperform Start Price: $2.88 ASTX Score: +15.52

great pipeline. bought at 2.01 with real money

Results 1 - 20 of 36 : 1 2 Next »

Featured Broker Partners


Advertisement